Myelodysplastic Syndrome
Myelodysplastic Syndrome (MDS) is a group of blood disorders where the bone marrow does not produce enough healthy blood cells, leading to symptoms like fatigue, weakness, and an increased risk of infections.
Myelodysplastic Syndrome: Targeted Treatment After Stem Cell Transplant
We are studying a new approach to prevent relapse and improve survival in patients with myelodysplastic syndrome after stem cell transplantation. The trial focuses on those with minimal residual disease to see if personalized treatment can help.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?
- Are you currently eligible for stem cell transplantation?
- Are you a female of childbearing potential and have you had a negative pregnancy test in the last 2 weeks?
- Do you have any uncontrolled medical conditions like high blood pressure or heart problems?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Azacitdine Clonmel
Azacitidin
Azacitidin Aliud
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Aarhus University Hospital
Clinical Medicine
Århus, Denmark
Rigshospitalet
Hematology
Copenhagen, Denmark
HUS-Yhtymae
Hematology
Helsinki, Finland
Sponsor: Karolinska University Hospital
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.